CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

upadacitinib

Last Updated: January 18, 2021
Result type: Reports
Project Number: SR0658-000
Product Line: Reimbursement Review

Generic Name: upadacitinib

Brand Name: Rinvoq

Manufacturer: AbbVie

Therapeutic Area: Psoriatic Arthritis, Adults.

Indications: Rinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more DMARDs. Rinvoq may be used as monotherapy or in combination with nonbiologic DMARDs.

Manufacturer Requested Reimbursement Criteria1: Indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more DMARDs. Rinvoq may be used as monotherapy or in combination with nonbiologic DMARDs.

Submission Type: Initial

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openNovember 27, 2020
Call for patient/clinician input closedJanuary 29, 2021
Submission receivedJanuary 04, 2021
Submission acceptedJanuary 18, 2021
Review initiatedJanuary 19, 2021
Draft CADTH review report(s) provided to sponsor for commentApril 05, 2021
Deadline for sponsors commentsApril 14, 2021
CADTH responses on draft review report(s) provided to sponsorJune 04, 2021
Expert committee meeting (initial)June 16, 2021
Draft recommendation issued to sponsorJune 28, 2021
To
June 30, 2021
Submit Feedback